MDR/IVDR Fundamentals

20 minFoundation

Learning Objectives

By the end of this module you will be able to:

  • 1Explain the purpose and scope of the EU Medical Device Regulation (MDR 2017/745) and In Vitro Diagnostic Regulation (IVDR 2017/746)
  • 2Identify the key changes introduced by MDR/IVDR compared to the previous Directives (MDD/IVDD)
  • 3Describe the transition timelines and how they affect healthcare facilities
  • 4Recognise the role of the HPRA as Ireland’s Competent Authority for medical devices
Content reviewed: March 2026
Educational content only β€” this training does not replace your facility's official policies or HPRA guidance. Not an accredited or verified course.

MDR/IVDR Fundamentals

20 minutes
Not Started

Why Does This Matter to You?

Real patient safety failures drove the EU to replace the old system

CASE STUDY

PIP Breast Implant Scandal

A French manufacturer used industrial-grade silicone instead of medical-grade in implants fitted to 400,000+ women across Europe. The old Directive system had no mechanism to detect this fraud before patients were harmed.

Fraudulent materialsNo traceabilityDelayed recall
CASE STUDY

Metal-on-Metal Hip Implants

Certain hip implants released metallic debris into patients' bloodstreams, causing tissue damage and requiring revision surgery in thousands of patients. The old system's post-market surveillance was too weak to catch the trend early.

Weak surveillanceNo trend detectionPatient harm

What MDR/IVDR Was Designed to Fix

πŸ›‘οΈ

Stronger Pre-Market Checks

Clinical evidence required before CE marking

πŸ”

Proactive Surveillance

Monitor every device throughout its lifetime

πŸ“Š

Full Traceability

UDI system tracks device from factory to patient

🌐

EUDAMED Database

Transparent public access to device safety data

M

MDR

(EU) 2017/745 Β· Applied May 2021

The Medical Devices Regulation governs everything from bandages to pacemakers β€” any instrument, software, or implant intended for a medical purpose.

Covers devices you use every day:

Infusion pumpsSurgical instrumentsHip implantsHospital bedsDefibrillatorsWound dressingsDiagnostic software

4

Risk Classes

I Β· IIa Β· IIb Β· III

22

Classification Rules

Annex VIII

I

IVDR

(EU) 2017/746 Β· Applied May 2022

The In Vitro Diagnostic Regulation governs devices that test specimens from the human body β€” blood, urine, tissue β€” outside the body.

Covers tests your lab runs daily:

Blood glucose stripsCOVID-19 rapid testsPregnancy testsBlood typing kitsLab analysersGenetic testsCompanion diagnostics

4

Risk Classes

A Β· B Β· C Β· D

7

Classification Rules

Annex VIII

The Regulatory Journey β€” Where Are We Now?

Click any milestone to expand details. Current transition deadlines are highlighted.

What Changed for Your Hospital?

Side-by-side: the old system vs what MDR/IVDR now requires

πŸ“‹ Clinical Evidence

❌ Old System

Literature review was often sufficient. Equivalence claims were loosely defined.

βœ… Under MDR/IVDR

Active clinical follow-up now required. Equivalence requires contractual access to the comparator device's technical documentation.

πŸ” Post-Market Surveillance

❌ Old System

Reactive β€” manufacturers only reported when something went wrong.

βœ… Under MDR/IVDR

Proactive and systematic. Manufacturers must have a PMS plan, submit Periodic Safety Update Reports (PSURs), and actively look for safety signals.

πŸ“Š Traceability

❌ Old System

No standardised tracking. If a batch was faulty, identifying affected patients could take weeks.

βœ… Under MDR/IVDR

Every device has a Unique Device Identifier (UDI). Hospitals must record UDIs β€” especially for Class III implantables β€” enabling targeted recalls within hours.

🏷️ Scope

❌ Old System

Traditional medical and IVD devices only. Many software products and aesthetic devices were unregulated.

βœ… Under MDR/IVDR

Now includes standalone medical software (SaMD), certain aesthetic devices (e.g. dermal fillers, coloured contact lenses), and genetic/companion diagnostic tests.

πŸ›οΈ Oversight of IVDs

❌ Old System

Under IVDD, ~80% of IVDs were self-certified by the manufacturer with no Notified Body involvement.

βœ… Under MDR/IVDR

Under IVDR, ~80% of IVDs now require Notified Body assessment. Independent third-party scrutiny is the norm, not the exception.

How a Device Gets to Your Ward

The MDR supply chain β€” every step has a responsible party and regulatory obligation

🏭
STEP 1

Manufacturer

Designs, manufactures, and places the device on the market

Responsible for CE marking, clinical evaluation, technical documentation, QMS, post-market surveillance, and vigilance reporting.

πŸ”¬
STEP 2

Notified Body

Independent assessment of higher-risk devices

Audits the manufacturer's quality system, reviews technical documentation, and issues the CE certificate for Class IIa, IIb, and III devices.

βœ…
STEP 3

CE Marking

The device is approved for the EU market

The CE mark means the device conforms to MDR requirements. It must be visible, legible, and indelible on the device or its packaging.

πŸš›
STEP 4

Distributor / Importer

Makes the device available on the market

Must verify CE marking, check EUDAMED for safety alerts, ensure proper storage conditions, and forward complaints to the manufacturer.

πŸ₯
STEP 5

Your Hospital

Procures, stores, and uses the device

Under Article 14: verify CE marking on receipt, maintain storage per IFU, record UDIs for implantables, report incidents to HPRA, cooperate with recalls.

πŸ‘©β€βš•οΈ
STEP 6

You β€” The Healthcare Worker

Uses the device on patients

Check device before use, follow IFU, report incidents through NIMS, preserve devices after incidents, act on Field Safety Notices.

Device Risk Classification β€” Visual Guide

The higher the class, the greater the risk and the stricter the regulatory scrutiny

MDR β€” Medical Devices

Class III

Highest Risk

Hip implants Β· Pacemakers Β· Stents

Class IIb

Medium-High Risk

Ventilators Β· X-ray machines Β· Infusion pumps

Class IIa

Medium Risk

Hearing aids Β· Ultrasound probes Β· Surgical clamps

Class I

Lowest Risk

Bandages Β· Tongue depressors Β· Wheelchairs

↑ More scrutiny Β· ↓ Less scrutiny

IVDR β€” In Vitro Diagnostics

Class D

Highest Risk

HIV/Hepatitis screening Β· Blood typing

Class C

Medium-High Risk

Companion diagnostics Β· Cancer markers Β· Genetic tests

Class B

Medium Risk

Pregnancy tests Β· Blood glucose strips Β· Self-tests

Class A

Lowest Risk

General lab reagents Β· Specimen containers Β· Wash buffers

↑ More scrutiny Β· ↓ Less scrutiny

Essential Definitions

The terms you will encounter throughout this training programme

Medical Device (MDR Article 2)

Any instrument, apparatus, appliance, software, implant, reagent, material or other article intended by the manufacturer for a medical purpose β€” where the principal action is not achieved by pharmacological, immunological, or metabolic means.

Hospital examples: Stethoscopes, surgical instruments, pacemakers, wheelchairs, diagnostic software, hospital beds, defibrillators

In Vitro Diagnostic (IVDR Article 2)

Any device intended to be used in vitro (outside the body) for examining specimens derived from the human body β€” providing information about physiological/pathological states, predispositions, safety with potential recipients, or therapeutic response.

Hospital examples: Blood glucose strips, pregnancy tests, COVID-19 rapid tests, lab analysers, blood typing kits, genetic tests

🎯 Key Takeaways from This Module

MDR and IVDR are EU Regulations β€” they apply directly in Ireland and replaced the older, weaker Directives that failed to prevent scandals like PIP and metal-on-metal hip recalls.

MDR governs medical devices (Class I–III). IVDR governs in vitro diagnostics (Class A–D). Both use risk-based classification β€” higher risk means more independent scrutiny.

Every device on the EU market must bear a CE mark. For higher-risk devices, a Notified Body must independently verify compliance before that mark is applied.

The UDI system gives every device a unique barcode. For Class III implantables, your hospital must record this β€” it is what enables targeted patient recalls within hours instead of weeks.

Post-market surveillance is no longer reactive. Manufacturers must proactively monitor every device throughout its lifetime and submit periodic safety update reports.

As a healthcare worker, you are part of this safety system. Recognising incidents, reporting through NIMS, and acting on Field Safety Notices are legal obligations β€” not optional best practices.

We are still in the transition period. Existing devices are being recertified under MDR/IVDR through 2028–2029. Check with clinical engineering if you are unsure about a device's regulatory status.

Irish Context β€” HPRA & HSE

In Ireland, the HPRA (Health Products Regulatory Authority) is the competent authority responsible for medical devices under both MDR and IVDR.

HSE facilities must comply with MDR/IVDR as end-users β€” this includes obligations around incident reporting, device traceability, and cooperating with manufacturers during recalls.

The HPRA publishes Medical Device Safety Notices and Field Safety Notices relevant to devices in use across Irish hospitals.

This is educational content only and is not an accredited or externally verified course. Always refer to official HPRA publications and your facility's own policies.

Knowledge Check

5 questions Β· 80% required to pass

Q1.What is the primary EU regulation governing medical devices (excluding IVDs)?

Q2.Which of the following is a key reason the EU introduced MDR/IVDR?

Q3.What does UDI stand for in the context of MDR?

Q4.Under MDR, what is the definition of a "medical device"?

Q5.When did the MDR (EU 2017/745) become fully applicable?

0/5 answered

Print-Friendly Summary

One-page PDF for ward reference & quick revision

Was this module useful?